Taken together, these results suggest that prolonged exposure of MCL1-inhibitory agents are likely to cause on-target cardiac toxicity, calling for the need for a potent MCL1 inhibitor with sufficient exposure to induce tumor apoptosis, yet a sufficiently short half-life to spare cardiotoxicity. The gene discussed is MCL1; the disease is neoplasm.